Trial Profile
A retrospective, cohort study to evaluate antitumor efficacy of Apatinib as a potential biomarker in patients with metastatic Gastric Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jun 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 24 Jun 2017 New trial record